List of CD20 monoclonal antibodies - Drugs.com
WEBCompare CD20 monoclonal antibodies. View important safety information, ratings, user reviews, popularity and more.
Anti-CD20 monoclonal antibodies: reviewing a revolution - PMC
WEBSep 6, 2018 · In this review, we will discuss the physiology of CD20 and its attractiveness as a therapeutic target, as well as the pharmacology, pre-clinical and clinical data for the major anti-CD20 monoclonal antibodies: rituximab, obinutuzumab and ofatumumab.
The regulation and function of CD20: an “enigma” of B-cell …
WEBNov 22, 2019 · Several small molecules (such as histone deacetylase inhibitors, DNA methyl-transferase inhibitors, aurora kinase A/B inhibitors, farnesyltransferase inhibitors, FOXO1 inhibitors, and bryostatin-1) are being tested to upregulate cell-surface CD20 levels and increase the efficacy of anti-CD20 monoclonal antibodies.
Next-generation anti-CD20 monoclonal antibodies in …
WEBNov 16, 2017 · Anti-CD20 monoclonal antibodies (mAbs) are used to achieve B cell depletion, and were initially developed to treat B cell proliferative disorders, including non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Anti-CD20 Agents for Multiple Sclerosis: Spotlight on
WEBOct 20, 2020 · Ocrelizumab, a humanized anti-CD20 monoclonal antibody, was approved in March 2017 by the Food and Drug Administration (FDA) and is also the first proven therapy to reduce disability progression in primary progressive MS.
Efficacy and safety of new anti-CD20 monoclonal antibodies …
WEBFeb 5, 2021 · Recently new anti-CD20 monoclonal antibodies (mAbs) have been developed, but their efficacy and safety compared with rituximab are still controversial.
The future of anti-CD20 monoclonal antibodies: are we making …
WEBMar 17, 2011 · Anti-CD20 mAbs have been shown to activate natural killer (NK) cells, macrophages, and neutrophils to eliminate B cells in vitro. 15,35,36 In contrast to these in vitro observations, there is now substantial preclinical evidence from mouse models indicating that macrophages are the key immune effector cells required for …
Rituximab (monoclonal anti-CD20 antibody): mechanisms of
WEBOct 23, 2003 · Rituximab, a chimeric monoclonal antibody that binds to CD20, was the first monoclonal antibody to be approved for clinical use in the therapy of cancer.
CD20 (Clusters of Differentiation 20) inhibitors - DrugBank Online
WEBCD20 (Clusters of Differentiation 20) inhibitors. A monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.
CD20 - Wikipedia
WEBCD20 is the target of the mAbs rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
- Some results have been removed